#United States #Miami #Viking Therapeutics #VKTX #metabolic disorders

Viking Therapeutics to Engage with Investors at Multiple Conferences in 2025

Viking Therapeutics, Inc. (NASDAQ: VKTX), a prominent clinical-stage biopharmaceutical firm, has announced its participation in several notable investor conferences scheduled for March 2025. These events are critical for the company as they continue to develop pioneering therapies targeting metabolic and endocrine disorders.

Upcoming Conferences Details

Viking's management will actively engage at the Leerink Partners Global Healthcare Conference 2025 and the Jefferies Biotech on the Beach Summit, both taking place in Miami, Florida.

Leerink Partners Global Healthcare Conference 2025

• - Dates: March 10-12, 2025
• - Fireside Chat Timing: March 11, 2025, from 9:20 to 9:50 AM Eastern
• - Location: Miami, FL

During this conference, Viking's team will not only be involved in a fireside chat but will also hold one-on-one meetings, providing an excellent platform to discuss their advancements and future plans. A live webcast of the fireside chat can be accessed on Viking Therapeutics’ website, with a replay option available post-conference.

Jefferies Biotech on the Beach Summit

• - Dates: March 11-12, 2025
• - Location: Miami, FL

At this summit, Viking’s management will focus exclusively on one-on-one meetings, allowing for in-depth discussions with investors about their research and development endeavors.

A Closer Look at Viking's Innovations

Viking Therapeutics is dedicated to creating innovative treatments for metabolic and endocrine disorders through a robust clinical pipeline. Currently, the company is advancing three compounds through clinical trials, with an emphasis on leveraging their expertise in metabolism to improve patient outcomes.

Key Therapeutics in Development

• - VK2735: This compound functions as a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, designed for metabolic disorder treatments. Earlier Phase 1 and Phase 2 trials indicated that VK2735 has an encouraging safety profile, while also showing positive clinical benefits. Viking is also exploring an oral version of this medication in ongoing Phase 1 trials.

• - VK2809: A novel oral small molecule selective thyroid hormone receptor beta agonist aimed at treating lipid and metabolic disorders. Recent Phase 2b studies achieved significant primary and secondary endpoints, particularly in treating biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Additionally, results from Phase 2a trials revealed notable reductions in LDL-C and liver fat content among patients treated with VK2809 compared to the placebo group.

• - VK0214: This new program targets X-linked adrenoleukodystrophy (X-ALD), a rare disease, utilizing an oral small molecule approach with promising early results from Phase 1b studies. Patients with the adrenomyeloneuropathy (AMN) form of X-ALD demonstrated significant reductions in plasma levels of very long-chain fatty acids following treatment with VK0214.

Conclusion

Viking Therapeutics stands at the forefront of innovation in the biopharmaceutical sector focusing on metabolic disorders. Their upcoming participation in these investor conferences signifies an important opportunity to share their advancements, foster connections, and possibly attract new investments. The insights shared during these events may illuminate Viking's future trajectory in the healthcare landscape, promising continued growth and development in the therapeutic areas they serve.

For further information about Viking Therapeutics, visit Viking Therapeutics.